George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Twice now, AI (Bing) has provided me answers with outdated "thinking". Firstly, it gave me the PM of Malaysia as being a bloke who's no longer in position and secondly, in response to my question, Is AVA6000 likely to succeed?, I got the following reply (Spot the mistake!)
AVA6000 is a novel precision medicine that is designed to target the tumor microenvironment via fibroblast activation protein (FAP) mediated cleavage1. It is based on a proprietary technology called pre|CISION™, which can generate chemotherapy prodrugs that are only activated in the presence of FAP2. FAP is overexpressed on the surface of activated fibroblastic cells, which are abundant in the supporting stroma of over 90% of malignant epithelial cancers1.
The potential benefit of AVA6000 is that it can deliver doxorubicin, a potent chemotherapeutic agent, directly to the tumor site, while reducing the exposure and toxicity to normal tissues1. Doxorubicin has been one of the most effective and widely used drugs for the treatment of various solid malignancies for over 40 years, but its clinical utility is limited by dose-limiting toxicities, including myelosuppression and cardiotoxicity1.
The success of AVA6000 depends on several factors, such as its safety, efficacy, pharmacokinetics, pharmacodynamics, and marketability. Currently, AVA6000 is in pre-clinical development and has not yet entered human trials2. Therefore, it is too early to predict its likelihood of success with certainty. However, based on the available data and reports, AVA6000 has shown promising results in in vitro and in vivo studies1. It has demonstrated significant anti-tumor activity and increased survival in several animal models with high FAP levels1. It has also shown a high degree of FAP specificity and resistance to hydrolysis by other mammalian peptidases1.
Therefore, AVA6000 seems to have a strong scientific rationale and a unique mechanism of action that could potentially offer a novel and effective treatment option for patients with various types of cancer. However, more research and clinical trials are needed to confirm its safety and efficacy in humans and to compare it with existing therapies. The development of AVA6000 is still in its early stages and there are many challenges and uncertainties ahead. Therefore, I cannot give you a definitive answer to your question, but I hope this information helps you understand more about this innovative drug. 😊
Predators or creditors? :)
Don't count on it as this is Aim and the MMs ain't stupid. They'll be fully aware of those thinking along your lines and will not therefore be looking to fill your pockets through their own predictability. The worrying thing here is how three large customers all backed-off all at the same time. Makes me wonder if a problem relating to the product became evident. Do not be surprised if this drops further tomorrow though.
I am not invested here, Ianbt, but as a long standing observer of this board I can say that jive_turkey is and continues to be one of the most knowledgeable and constructive posters on here. Your latest post suggests to me that you are a polar opposite who belongs in the school playground. The irony of you calling someone else moronic will not be lost on others who read your post.
There are a lot of good people on this board who've been here for a fair while, those who offer contrarian views within some of the conversations which have taken place included. This share doesn't fall within my current investment criteria but I keep an eye on it and really hope that it continues to come good for the patients, the characters and posters here who've shared so much valuable researcher over the years. Whatever happens, the entertainment value has been top drawer and my gut feeling tells me that good news is pretty close now.
............not with that spread though.
Contrarian123, I'm not invested here but having just read your posts I was reminded of Waldo & Statler.
Https://www.londonstockexchange.com/news-article/TIFS/director-pdmr-shareholding/16094474
...Reported by CNBC
Dick’s shares fall 24% as retailer slashes outlook over theft concerns
PUBLISHED TUE, AUG 22 20237:01 AM EDT
Dick’s Sporting Goods reported a profit drop and cut its earnings outlook for the year after seeing an uptick in retail theft and slow sales in its outdoor category.
It’s the first reference the athletic goods retailer has made to shrink in a press release in nearly 20 years.
In a rare miss, Dick’s also fell short of Wall Street’s estimates on both the top and bottom lines.
On the DX front, I got the impression a while ago that AS has an eye on the home testing (LFT) market and is keen to take larger market share on that front. I like that in it's own right but imagine another pandemic was to strike - including an upgraded Covid strain; The SP would go through the roof. That aside, is he positioning us for a launch of a new branded range. Just speculation on my part but he hasn't expanded that side of the house just for fun.
Skycity1
Try not to be so transparent with your agenda, as all too clearly illustrated through your posts on here to date. You would not be checking-in here so regularly if you did not see these as a worthwhile longer term buy.
Unpopular as it might make me, Wyn's assessment is exactly the same as the one I concluded when revisiting the RNS's after a period away from this BB. AS's wording, as highlighted by Wyn, can be taken either way. What has not helped my rush to rebuy is the nagging thought of the incident many moons ago when AS said "There will be no fundraise", a statement that was shortly followed by a fundraise; old hands on here will remember that all too well. By contrast in this context, AS's wording to date could be taken as "holding statements" in the knowledge that he believes (obviously hopes?) they MAY reach a point whereby hugely significant amounts of Dox are being released into the tumour under the doseage to date but even he hasn't seen that yet. A case can be made here for both arguments (Wyn & Ice) which makes this a punt, imo at least.